Janux Therapeutics, Inc.
JANX
$13.15
-$0.47-3.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.36M | -31.95M | -24.31M | -33.86M | -23.51M |
| Total Depreciation and Amortization | 469.00K | 468.00K | 501.00K | 541.00K | 519.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.65M | 5.99M | 4.42M | 5.75M | 6.48M |
| Change in Net Operating Assets | 4.91M | -3.06M | 6.54M | 3.75M | -516.00K |
| Cash from Operations | -12.34M | -28.54M | -12.86M | -23.81M | -17.02M |
| Capital Expenditure | -273.00K | -106.00K | -93.00K | -473.00K | -371.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.56M | 29.65M | 8.40M | 2.04M | -340.02M |
| Cash from Investing | 8.29M | 29.54M | 8.31M | 1.56M | -340.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.55M | 2.94M | 493.00K | 954.00K | 901.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 0.00 | -347.00K |
| Cash from Financing | 3.55M | 2.94M | 493.00K | 954.00K | 554.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -506.00K | 3.95M | -4.06M | -21.30M | -356.86M |